The Mclean Hospital Corporation

The Mclean Hospital Corporation Research Management Division, doing business as Mclean Hospital, is a non-profit psychiatric teaching hospital affiliated with Harvard Medical School located in Belmont, Massachusetts. As a leading neuroscience and mental health research institution, McLean Hospital provides the federal government with specialized scientific research services, clinical expertise, and advanced neurobiological investigation capabilities across multiple domains of psychiatric and neurological disorders. The institution combines clinical, research, and academic missions to advance translational neuroscience and support federal research initiatives in mental health, substance abuse, and related neurobiological fields.

McLean Hospital has demonstrated substantial capacity in federal contracting, securing multiple prime federal contract awards from agencies including the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA). The hospital's most significant contract is a $34.5 million cost-plus-no-fee definitive contract with NIDA to establish and operate a collection site for the NIH NeuroBank Brain and Tissue Repository, running from November 2025 through October 2030. Under this contract, McLean Hospital actively acquires, processes, stores, curates, preserves, and distributes central nervous system tissue and related materials to support neurological, psychiatric, and neurodevelopmental disorder research, with minimum performance targets of at least 70 donors annually. Additional DEA contracts include blanket purchase agreements for specialized scientific services related to benzodiazepine testing and the assessment of potential substance abuse treatment medications in nonhuman primate models, with a definitive contract valued at $2.69 million for the latter work. A DEA blanket purchase agreement totaling $1.06 million over five years enables the agency to access McLean's specialized expertise in monitoring and regulating controlled substances and emerging drugs. All contract awards to McLean Hospital have been made without set-aside designations under full and open competition, reflecting the institution's demonstrated technical expertise and capability in executing complex federal research contracts.

McLean Hospital maintains an extensive federal grant portfolio spanning multiple National Institutes of Health institutes and other federal agencies, demonstrating exceptional strength in obtaining peer-reviewed research funding. The hospital has received significant project grants from the National Institute of Mental Health (NIMH) totaling millions of dollars for research on depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, anxiety disorders, and other psychiatric conditions. Recent NIMH awards include $1.43 million for research on detecting affective disturbance and depression risk in adolescents using smartphone technology, $792,441 for tracking stress responses in female adolescents at familial risk for depression, and $777,016 for investigating synaptic mechanisms of continuous theta burst stimulation in treating depression. The National Institute on Drug Abuse has awarded grants totaling over $352,000 for developing and validating patient-reported outcome measures for substance use disorders and over $208,000 for mentoring early-career investigators in patient-oriented research on substance use disorders. McLean has also received substantial funding from the National Institute of General Medical Sciences ($2.05 million for decoding neural foundations of sexual dimorphisms in aggression), Defense Health Agency ($1.6 million for investigating APOE and lipid mechanisms in Parkinson's disease cognitive dysfunction), the National Institute of Neurological Disorders and Stroke (multiple grants totaling over $2 million for Parkinson's disease research and OCD biomarkers), and the Defense Advanced Research Projects Agency ($7.84 million cooperative agreement for cognitive and emotional flexibility interventions). The institution serves as both prime grantee and subcontractor on numerous multi-site federally funded research initiatives, with research conducted across psychiatric neuroscience, translational neurobiology, computational psychiatry, and clinical neuroscience domains. These grants support training programs, conference support, and infrastructure improvements, including a $1.1 million grant for upgrading a 9.4 Tesla preclinical magnetic resonance imaging system.

McLean Hospital holds a single-award Blanket Purchase Agreement (BPA) with the Drug Enforcement Administration, established on May 1, 2024, with a five-year ceiling value of $1,062,961.53 extending through April 30, 2029. This BPA serves as an indefinite delivery, indefinite quantity vehicle enabling the DEA to issue task orders for specialized scientific expertise in monitoring and regulating controlled substances, regulated chemicals, and emerging drugs. Under this IDV framework, McLean Hospital has already received task order calls, including a $141,455.48 firm fixed-price call for benzodiazepine testing with performance through July 13, 2026, and previous task orders demonstrating the hospital's sustained capacity to support DEA regulatory science missions. The BPA does not fall under a parent federal contract vehicle but operates as a standalone DEA acquisition instrument. This contract vehicle leverages McLean Hospital's established clinical research capabilities and expertise in substance abuse and psychiatric pharmacology, positioning the institution as a preferred source for the federal government's specialized scientific investigations supporting drug regulatory functions and public health initiatives related to controlled substance monitoring and emerging drug characterization.